Use of Remdesivir in the treatment of Covid-19: na integrative review
DOI:
https://doi.org/10.33448/rsd-v11i3.26420Keywords:
Covid-19; Sars-CoV-2; Coronavírus; Treatment; Remdesivir; Pandemic; Review.Abstract
The present study aimed to determine the efficacy, effectiveness and safety of Remdesivir in the treatment of Covid-19 through an integrative review. The search for articles was carried out in March 2021 in the Pubmed, Scielo, Embase and Cochrane databases. To guide this research, the guiding question was raised: “What is the role of Remdesivir in the treatment of Covid-19 in humans?”. The descriptors “Covid or Sars-Cov-2 or Coronavirus” and “treatment” and “Remdesivir” were used. Inclusion criteria were original primary studies that addressed the proposed topic, available in full, between 2019-2021, in Portuguese or English. Of the 3012 articles found, 17 were used that met the inclusion criteria. Most of the studies found reported an improvement in the condition of patients treated with Remdesivir, but it is important to note that therapy with the drug also had several side effects and did not change the mortality rate. Based on the data analyzed, Remdesivir showed promising results, suggesting a favorable risk-benefit profile, but as far as was observed, the rate of deaths was not altered and its prolonged use can trigger undesirable side effects.
References
Ackley, T. W., McManus, D., Topal, J. E., Cicali, B., & Shah, S. (2021). A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort. Antimicrobial agents and chemotherapy, 65(2), e02290-20. https://doi.org/10.1128/AAC.02290-20
Aiswarya, D., Arumugam, V., Dineshkumar, T., Gopalakrishnan, N., Lamech, T. M., Nithya, G., Sastry, B., Vathsalyan, P., Dhanapriya, J., & Sakthirajan, R. (2021). Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance. Kidney international reports, 6(3), 586–593. https://doi.org/10.1016/j.ekir.2020.12.003
Anvisa. Agência Nacional de Vigilância Sanitária. (2021). Anvisa aprova registro da vacina da Fiocruz/AstraZeneca e de medicamento contra o coronavírus. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2021/anvisa-aprova-registro-da-vacina-da-fiocruz-astrazeneca-e-de-medicamento-contra-o-coronavirus
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., Touloumi, G., … ACTT-1 Study Group Members (2020). Remdesivir for the Treatment of Covid-19 - Final Report. The New England journal of medicine, 383(19), 1813–1826. https://doi.org/10.1056/NEJMoa2007764
Céspedes, M., & Souza, J. (2020). Sars-CoV-2: A clinical update - II. Revista da Associação Medica Brasileira, 66(4), 547–557. https://doi.org/10.1590/1806-9282.66.4.547
ClinicalTrials.gov (2021). Views of COVID-19 Studies Listed on ClinicalTrials.gov (Beta). http://clinicaltrials.gov
Dande, R., Qureshi, A., Persaud, K., Puri, C., Zulfiqar, S., & Awasthi, S. (2021). Remdesivir in a pregnant patient with COVID-19 pneumonia. Journal of community hospital internal medicine perspectives, 11(1), 103–106. https://doi.org/10.1080/20009666.2020.1857510
Dubert, M., Visseaux, B., Isernia, V., Bouadma, L., Deconinck, L., Patrier, J., Wicky, P. H., Le Pluart, D., Kramer, L., Rioux, C., Le Hingrat, Q., Houhou-Fidouh, N., Yazdanpanah, Y., Ghosn, J., & Lescure, F. X. (2020). Case report study of the first five COVID-19 patients treated with Remdesivir in France. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 98, 290–293. https://doi.org/10.1016/j.ijid.2020.06.093
Flisiak, R., Zarębska-Michaluk, D., Berkan-Kawińska, A., Tudrujek-Zdunek, M., Rogalska, M., Piekarska, A., Kozielewicz, D., Kłos, K., Rorat, M., Bolewska, B., Szymanek-Pasternak, A., Mazur, W., Lorenc, B., Podlasin, R., Sikorska, K., Oczko-Grzesik, B., Iwaszkiewicz, C., Szetela, B., Pabjan, P., Pawłowska, M., … Jaroszewicz, J. (2021). Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study. Polish archives of internal medicine, 131(1), 103–110. https://doi.org/10.20452/pamw.15735
Goldman, J. D., Lye, D., Hui, D. S., Marks, K. M., Bruno, R., Montejano, R., Spinner, C. D., Galli, M., Ahn, M. Y., Nahass, R. G., Chen, Y. S., SenGupta, D., Hyland, R. H., Osinusi, A. O., Cao, H., Blair, C., Wei, X., Gaggar, A., Brainard, D. M., Towner, W. J., … GS-US-540-5773 Investigators (2020). Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. The New England journal of medicine, 383(19), 1827–1837. https://doi.org/10.1056/NEJMoa2015301
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F. X., Nicastri, E., Oda, R., Yo, K., Quiros-Roldan, E., Studemeister, A., Redinski, J., Ahmed, S., Bernett, J., Chelliah, D., Chen, D., … Flanigan, T. (2020). Compassionate Use of Remdesivir for Patients with Severe Covid-19. The New England journal of medicine, 382(24), 2327–2336. https://doi.org/10.1056/NEJMoa2007016
Helleberg, M., Niemann, C. U., Moestrup, K. S., Kirk, O., Lebech, A. M., Lane, C., & Lundgren, J. (2020). Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy. The Journal of infectious diseases, 222(7), 1103–1107. https://doi.org/10.1093/infdis/jiaa446
Igbinosa, I., Miller, S., Bianco, K., Nelson, J., Kappagoda, S., Blackburn, B. G., Grant, P., Subramanian, A., Lyell, D. J., El-Sayed, Y. Y., & Aziz, N. (2020). Use of Remdesivir for pregnant patients with severe novel coronavirus disease 2019. American journal of obstetrics and gynecology, 223(5), 768–770. https://doi.org/10.1016/j.ajog.2020.08.001
Joo, E. J., Ko, J. H., Kim, S. E., et. al. Kang, S. J., Baek, J. H., Heo, E. Y., Shi, H. J., Eom, J. S., Choe, P. G., Bae, S., Ra, S. H., Kim, D. Y., Kim, B. N., Kang, Y. M., Kim, J. Y., Chung, J. W., Chang, H. H., Bae, S., Cheon, S., Park, Y., … Peck, K. R. (2021). Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study. Journal of Korean medical science, 36(11), e83. https://doi.org/10.3346/jkms.2021.36.e83
Kalil, A. C., Patterson, T. F., Mehta, A. K., Tomashek, K. M., Wolfe, C. R., Ghazaryan, V., Marconi, V. C., Ruiz-Palacios, G. M., Hsieh, L., Kline, S., Tapson, V., Iovine, N. M., Jain, M. K., Sweeney, D. A., El Sahly, H. M., Branche, A. R., Regalado Pineda, J., Lye, D. C., Sandkovsky, U., Luetkemeyer, A. F., … ACTT-2 Study Group Members (2021). Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. The New England journal of medicine, 384(9), 795–807. https://doi.org/10.1056/NEJMoa2031994
Méndez-Echevarría, A., Pérez-Martínez, A., Gonzalez Del Valle, L., Ara, M. F., Melendo, S., Ruiz de Valbuena, M., Vazquez-Martinez, J. L., Morales-Martínez, A., Remesal, A., Sándor-Bajusz, K. A., Cabañas, F., & Calvo, C. (2021). Compassionate use of Remdesivir in children with COVID-19. European journal of pediatrics, 180(4), 1317–1322. https://doi.org/10.1007/s00431-020-03876-1
Menezes, A.M., & Santos, I.S. (1999). Curso de epidemiologia básica para pneumologistas. 4ª parte - Epidemiologia clínica. Jornal De Pneumologia, 25, 321-326. https://doi.org/10.1590/S0102-35861999000600005
National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 121304016, Remdesivir. Retrieved March 16, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/Remdesivir
Pasquini, Z., Montalti, R., Temperoni, C., Canovari, B., Mancini, M., Tempesta, M., Pimpini, D., Zallocco, N., & Barchiesi, F. (2020). Effectiveness of Remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. The Journal of antimicrobial chemotherapy, 75(11), 3359–3365. https://doi.org/10.1093/jac/dkaa321
Riera, R., Pacheco, R. L., Latorraca, C. O. C., Fontes, L. E., Martimbianco, A. L. C. (2020). Remdesivir para infecção por SARS-CoV-2 (COVID-19). Revisão sistemática. https://oxfordbrazilebm.com/index.php/2020/05/30/Remdesivir-para-infeccao-por-sars-cov-2-Covid-19-revisao-sistematica2/
Santos, C. M. C., Pimenta, C. A. M., & Nobre, M. R. C. (2007). A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Revista Latino-Americana De Enfermagem, 15(3), 508-511. https://doi.org/10.1590/S0104-11692007000300023
Souza, M. T., Silva, M. D., & Carvalho, R. (2010). Revisão integrativa: o que é e como fazer. Einstein, 8(1), 102–106. https://doi.org/10.1590/s1679-45082010rw1134
Spinner, C. D., Gottlieb, R. L., Criner, G. J., Arribas López, J. R., Cattelan, A. M., Soriano Viladomiu, A., Ogbuagu, O., Malhotra, P., Mullane, K. M., Castagna, A., Chai, L., Roestenberg, M., Tsang, O., Bernasconi, E., Le Turnier, P., Chang, S. C., SenGupta, D., Hyland, R. H., Osinusi, A. O., Cao, H., … GS-US-540-5774 Investigators (2020). Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA, 324(11), 1048–1057. https://doi.org/10.1001/jama.2020.16349
Tempestilli, M., Caputi, P., Avataneo, V., Notari, S., Forini, O., Scorzolini, L., Marchioni, L., Ascoli Bartoli, T., Castilletti, C., Lalle, E., Capobianchi, M. R., Nicastri, E., D'Avolio, A., Ippolito, G., Agrati, C., & COVID 19 INMI Study Group (2020). Pharmacokinetics of Remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. The Journal of antimicrobial chemotherapy, 75(10), 2977–2980. https://doi.org/10.1093/jac/dkaa239
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 323(11), 1061–1069. https://doi.org/10.1001/jama.2020.1585
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., Wang, Y., … Wang, C. (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (London, England), 395(10236), 1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-9
Who. (2020) Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-Covid-19---11-march-2020
Yang, W., Cao, Q., Qin, L., Wang, X., Cheng, Z., Pan, A., Dai, J., Sun, Q., Zhao, F., Qu, J., & Yan, F. (2020). Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. The Journal of infection, 80(4), 388–393. https://doi.org/10.1016/j.jinf.2020.02.016
Yin, R.K. (2009). A Review of Case Study Research: Design and Methods. Thousand Oaks, CA: Sage. 5(4). 206-207.
Zhang, L., & Liu, Y. (2020). Potential interventions for novel coronavirus in China: A systematic review. Journal of medical virology, 92(5), 479–490. https://doi.org/10.1002/jmv.25707
Zhang, T., Wu, Q., & Zhang, Z. (2020). Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. Current biology : CB, 30(8), 1578. https://doi.org/10.1016/j.cub.2020.03.063
Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. D., Liu, M. Q., Chen, Y., Shen, X. R., Wang, X., Zheng, X. S., & Shi, Z. L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273. https://doi.org/10.1038/s41586-020-2012-7
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Gabrielly Alves Malacrida; Gabriel Henrique Maximino Santos; Valéria Cataneli Pereira; Rogéria Keller
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
